Cargando…

Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea

Laboratory-specific reference values for cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers are necessary. Our objective was to apply well-known CSF biomarkers and redetermine their diagnostic cutoff values for AD in South Korea. CSF samples from matched control subjects (n=71), patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sun Ah, Chae, Won Seok, Kim, Hyeong Jun, Shin, Ho Sik, Kim, Saeromi, Im, Ji Young, Ahn, Sang Il, Min, Kyoung Dae, Yim, Soo Jae, Ye, Byoung Seok, Seo, Sang Won, Jeong, Jee Hyang, Park, Kyung Won, Choi, Seong Hye, Na, Duk L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325243/
https://www.ncbi.nlm.nih.gov/pubmed/28030437
http://dx.doi.org/10.1097/WAD.0000000000000184
_version_ 1782510343218528256
author Park, Sun Ah
Chae, Won Seok
Kim, Hyeong Jun
Shin, Ho Sik
Kim, Saeromi
Im, Ji Young
Ahn, Sang Il
Min, Kyoung Dae
Yim, Soo Jae
Ye, Byoung Seok
Seo, Sang Won
Jeong, Jee Hyang
Park, Kyung Won
Choi, Seong Hye
Na, Duk L.
author_facet Park, Sun Ah
Chae, Won Seok
Kim, Hyeong Jun
Shin, Ho Sik
Kim, Saeromi
Im, Ji Young
Ahn, Sang Il
Min, Kyoung Dae
Yim, Soo Jae
Ye, Byoung Seok
Seo, Sang Won
Jeong, Jee Hyang
Park, Kyung Won
Choi, Seong Hye
Na, Duk L.
author_sort Park, Sun Ah
collection PubMed
description Laboratory-specific reference values for cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers are necessary. Our objective was to apply well-known CSF biomarkers and redetermine their diagnostic cutoff values for AD in South Korea. CSF samples from matched control subjects (n=71), patients with AD dementia (ADD, n=76), and other neurological disorders with cognitive decline (OND, n=47) were obtained from 6 Korean dementia clinics according to a standardized protocol. CSF biomarker concentrations were measured using enzyme-linked immunosorbent assay. CSF biomarkers differed significantly between the ADD and control groups (P<0.001 for all), and between the ADD and OND groups (P<0.001 for all). The areas under the curve in differentiation of ADD from control subjects were 0.97 for Aβ42, 0.93 for total tau (tTau), 0.86 for pTau, and 0.99 for both tTau/Aβ42 and pTau/Aβ42 ratios. Our revised cutoff value for Aβ42 was higher than our previous one, whereas the values for the Tau proteins were similar. The tTau/Aβ42 ratio had the highest accuracy, 97%. Our findings highlight the usefulness of CSF AD biomarkers in South Korea, and the necessity of continually testing the reliability of cutoff values.
format Online
Article
Text
id pubmed-5325243
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-53252432017-03-08 Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea Park, Sun Ah Chae, Won Seok Kim, Hyeong Jun Shin, Ho Sik Kim, Saeromi Im, Ji Young Ahn, Sang Il Min, Kyoung Dae Yim, Soo Jae Ye, Byoung Seok Seo, Sang Won Jeong, Jee Hyang Park, Kyung Won Choi, Seong Hye Na, Duk L. Alzheimer Dis Assoc Disord Original Articles Laboratory-specific reference values for cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers are necessary. Our objective was to apply well-known CSF biomarkers and redetermine their diagnostic cutoff values for AD in South Korea. CSF samples from matched control subjects (n=71), patients with AD dementia (ADD, n=76), and other neurological disorders with cognitive decline (OND, n=47) were obtained from 6 Korean dementia clinics according to a standardized protocol. CSF biomarker concentrations were measured using enzyme-linked immunosorbent assay. CSF biomarkers differed significantly between the ADD and control groups (P<0.001 for all), and between the ADD and OND groups (P<0.001 for all). The areas under the curve in differentiation of ADD from control subjects were 0.97 for Aβ42, 0.93 for total tau (tTau), 0.86 for pTau, and 0.99 for both tTau/Aβ42 and pTau/Aβ42 ratios. Our revised cutoff value for Aβ42 was higher than our previous one, whereas the values for the Tau proteins were similar. The tTau/Aβ42 ratio had the highest accuracy, 97%. Our findings highlight the usefulness of CSF AD biomarkers in South Korea, and the necessity of continually testing the reliability of cutoff values. Lippincott Williams & Wilkins 2017-01 2016-12-23 /pmc/articles/PMC5325243/ /pubmed/28030437 http://dx.doi.org/10.1097/WAD.0000000000000184 Text en Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CreativeCommonsAttribution-NonCommercial-NoDerivativesLicense4.0) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Articles
Park, Sun Ah
Chae, Won Seok
Kim, Hyeong Jun
Shin, Ho Sik
Kim, Saeromi
Im, Ji Young
Ahn, Sang Il
Min, Kyoung Dae
Yim, Soo Jae
Ye, Byoung Seok
Seo, Sang Won
Jeong, Jee Hyang
Park, Kyung Won
Choi, Seong Hye
Na, Duk L.
Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
title Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
title_full Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
title_fullStr Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
title_full_unstemmed Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
title_short Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
title_sort cerebrospinal fluid biomarkers for the diagnosis of alzheimer disease in south korea
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325243/
https://www.ncbi.nlm.nih.gov/pubmed/28030437
http://dx.doi.org/10.1097/WAD.0000000000000184
work_keys_str_mv AT parksunah cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT chaewonseok cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT kimhyeongjun cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT shinhosik cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT kimsaeromi cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT imjiyoung cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT ahnsangil cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT minkyoungdae cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT yimsoojae cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT yebyoungseok cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT seosangwon cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT jeongjeehyang cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT parkkyungwon cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT choiseonghye cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea
AT nadukl cerebrospinalfluidbiomarkersforthediagnosisofalzheimerdiseaseinsouthkorea